DRG Epidemiology’s coverage of Crohn’s disease (CD) comprises epidemiological estimates of key patient populations across the mature (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) and emerging pharmaceutical markets (Brazil, China, India, Mexico, Russia, South Korea, and Turkey), as well as countries in the Americas, Asia-Pacific, Europe, Middle East, and Africa. We report the diagnosed prevalence of CD for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and over 10 years for the other countries covered in this report.

DRG Epidemiology’s CD forecast will answer the following questions:

  • Of all people with CD, how many in each country have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CD over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.

In addition to the total number of cases for each forecast year, DRG Epidemiology provides at least ten years of forecast data for the following CD subpopulations:

  • Incident cases by diagnosis status.
  • Diagnosed prevalent cases by disease location.
  • Diagnosed prevalent cases by disease behavior.

Note: Coverage may vary by country.

Table of contents

  • Crohn's Disease - Epidemiology - Americas
    • Introduction
      • Key Findings
        • Overview
          • Prevalence of Crohn's Disease per 100,000 Among People of All Ages in 2018 and 2028
          • Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Crohn's Disease over the Next Ten Years
          • Analysis of Diagnosed Prevalent Cases of Crohn's Disease in the Countries Under Study in 2018 by Disease Behavior
      • Epidemiology Data
      • Methods
        • Diagnosed Prevalent Cases
        • Diagnosed Incident Cases
        • Disease Location
        • Disease Behavior
        • Disease Severity
        • Drug-Treated Cases
        • Lifetime DALYs Gained
      • Reference Materials
        • Literature Review
          • Studies Included in the Analysis of Crohn's Disease
          • Studies Excluded in the Analysis of Crohn's Disease
        • Risk/Protective Factors
          • Bibliography

      Author(s): Abey John, M.P.H.

      Abey John, M.P.H., is an epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked with Jhpiego (an affiliate of Johns Hopkins Medical University) in implementing family planning health programs in India in collaboration with the government of India. He also has worked at the grassroots level as a health team manager to help the rural population living in the foothills of the Himalayas. He holds a master’s degree in public health.

       


      Related Reports

      Crohn's Disease - Landscape & Forecast - Disease Landscape & Forecast

      The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. T...

      View Details

      Crohn's Disease | Disease Landscape and Forecast | G7 | 2020

      The Crohn’s disease (CD) therapy market is expected to see increasing use of biologics / targeted oral therapies and grow steadily over the next decade. The well-established TNF-α inhibitors (e.g.,...

      View Details